209 related articles for article (PubMed ID: 36591261)
1. Transcriptome profiling of osteoclast subsets associated with arthritis: A pathogenic role of CCR2
Filipović M; Flegar D; Aničić S; Šisl D; Kelava T; Kovačić N; Šućur A; Grčević D
Front Immunol; 2022; 13():994035. PubMed ID: 36591261
[TBL] [Abstract][Full Text] [Related]
2. Preventive CCL2/CCR2 Axis Blockade Suppresses Osteoclast Activity in a Mouse Model of Rheumatoid Arthritis by Reducing Homing of CCR2
Flegar D; Filipović M; Šućur A; Markotić A; Lukač N; Šisl D; Ikić Matijašević M; Jajić Z; Kelava T; Katavić V; Kovačić N; Grčević D
Front Immunol; 2021; 12():767231. PubMed ID: 34925336
[TBL] [Abstract][Full Text] [Related]
3. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells.
Sucur A; Jajic Z; Artukovic M; Matijasevic MI; Anic B; Flegar D; Markotic A; Kelava T; Ivcevic S; Kovacic N; Katavic V; Grcevic D
Arthritis Res Ther; 2017 Jun; 19(1):142. PubMed ID: 28619088
[TBL] [Abstract][Full Text] [Related]
4. Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.
Ikić Matijašević M; Flegar D; Kovačić N; Katavić V; Kelava T; Šućur A; Ivčević S; Cvija H; Lazić Mosler E; Kalajzić I; Marušić A; Grčević D
Clin Exp Immunol; 2016 Dec; 186(3):321-335. PubMed ID: 27612450
[TBL] [Abstract][Full Text] [Related]
5. Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.
Sućur A; Katavić V; Kelava T; Jajić Z; Kovačić N; Grčević D
Int Orthop; 2014 Sep; 38(9):1893-903. PubMed ID: 24913769
[TBL] [Abstract][Full Text] [Related]
6. Intestinal Inflammation Promotes MDL-1
Peek CT; Ford CA; Eichelberger KR; Jacobse J; Torres TP; Maseda D; Latour YL; Piazuelo MB; Johnson JR; Byndloss MX; Wilson KT; Rathmell JC; Goettel JA; Cassat JE
Cell Mol Gastroenterol Hepatol; 2022; 14(4):731-750. PubMed ID: 35835390
[TBL] [Abstract][Full Text] [Related]
7. RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens.
Mensah KA; Ritchlin CT; Schwarz EM
J Cell Physiol; 2010 Apr; 223(1):76-83. PubMed ID: 20039274
[TBL] [Abstract][Full Text] [Related]
8. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.
Moreaux J; Hose D; Kassambara A; Reme T; Moine P; Requirand G; Goldschmidt H; Klein B
Blood; 2011 Jan; 117(4):1280-90. PubMed ID: 21097672
[TBL] [Abstract][Full Text] [Related]
10. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss.
Collins FL; Williams JO; Bloom AC; Singh RK; Jordan L; Stone MD; McCabe LR; Wang ECY; Williams AS
Bone; 2017 Apr; 97():94-104. PubMed ID: 28062298
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model.
Tanaka K; Hashizume M; Mihara M; Yoshida H; Suzuki M; Matsumoto Y
Clin Exp Immunol; 2014 Feb; 175(2):172-80. PubMed ID: 24028747
[TBL] [Abstract][Full Text] [Related]
12. Curcumin suppresses RANKL-induced osteoclast precursor autophagy in osteoclastogenesis by inhibiting RANK signaling and downstream JNK-BCL2-Beclin1 pathway.
Ke D; Xu H; Han J; Dai H; Wang X; Luo J; Yu Y; Xu J
Biomed J; 2024 Feb; 47(1):100605. PubMed ID: 37179010
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression.
Yao Z; Li P; Zhang Q; Schwarz EM; Keng P; Arbini A; Boyce BF; Xing L
J Biol Chem; 2006 Apr; 281(17):11846-55. PubMed ID: 16461346
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism.
Yao Z; Xing L; Qin C; Schwarz EM; Boyce BF
J Biol Chem; 2008 Apr; 283(15):9917-24. PubMed ID: 18250170
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function.
Charles JF; Hsu LY; Niemi EC; Weiss A; Aliprantis AO; Nakamura MC
J Clin Invest; 2012 Dec; 122(12):4592-605. PubMed ID: 23114597
[TBL] [Abstract][Full Text] [Related]
17. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells.
Grevers LC; de Vries TJ; Everts V; Verbeek JS; van den Berg WB; van Lent PL
Ann Rheum Dis; 2013 Feb; 72(2):278-85. PubMed ID: 22918932
[TBL] [Abstract][Full Text] [Related]
18. Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells.
Blüml S; Friedrich M; Lohmeyer T; Sahin E; Saferding V; Brunner J; Puchner A; Mandl P; Niederreiter B; Smolen JS; Schabbauer G; Redlich K
Ann Rheum Dis; 2015 Jan; 74(1):227-33. PubMed ID: 24078675
[TBL] [Abstract][Full Text] [Related]
19. Puerarin inhibits the migration of osteoclast precursors and osteoclastogenesis by inhibiting MCP-1 production.
Lin S; Ke D; Lin Y; Fu X; Yu Y
Biosci Biotechnol Biochem; 2020 Jul; 84(7):1455-1459. PubMed ID: 32154764
[TBL] [Abstract][Full Text] [Related]
20. Delivery of miR-146a to Ly6C
Ammari M; Presumey J; Ponsolles C; Roussignol G; Roubert C; Escriou V; Toupet K; Mausset-Bonnefont AL; Cren M; Robin M; Georgel P; Nehmar R; Taams L; Grün J; Grützkau A; Häupl T; Pers YM; Jorgensen C; Duroux-Richard I; Courties G; Apparailly F
Theranostics; 2018; 8(21):5972-5985. PubMed ID: 30613275
[No Abstract] [Full Text] [Related]
[Next] [New Search]
